Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
NCT ID: NCT04171141
Last Updated: 2025-01-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
79 participants
INTERVENTIONAL
2019-11-19
2023-11-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229
Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer
NCT04149015
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
NCT06417892
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors
NCT00515216
Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy
NCT00087503
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Escalation
Single Agent Dose Escalation
PF-07062119
PF-07062119
Dose Finding Anti-PD-1 Combination
Part 1B PF-07062119 plus anti-PD-1
PF-07062119
PF-07062119
Anti-PD1
Anti-PD1 PF-06801591
Dose Finding anti-VEGF Combination
Part 1B PF-07062119 plus anti-VEGF
PF-07062119
PF-07062119
Anti-VEGF
Anti-VEGF IV (bevacizumab)
Dose Expansion Arm A
PF-07062119 as a Single Agent in CRC
PF-07062119
PF-07062119
Dose Expansion Arm B
PF-07062119 in Combination with anti-PD-1 in CRC
PF-07062119
PF-07062119
Dose Expansion Arm C
PF-07062119 in Combination with anti-VEGF in CRC
PF-07062119
PF-07062119
Anti-PD1
Anti-PD1 PF-06801591
Anti-VEGF
Anti-VEGF IV (bevacizumab)
Dose Expansion Arm D
PF-07062119 in Combination with either anti-PD-1 or anti-VEGF in various Tumor Types
PF-07062119
PF-07062119
Anti-PD1
Anti-PD1 PF-06801591
Anti-VEGF
Anti-VEGF IV (bevacizumab)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-07062119
PF-07062119
Anti-PD1
Anti-PD1 PF-06801591
Anti-VEGF
Anti-VEGF IV (bevacizumab)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For Part 2, diagnosis of colorectal adenocarcinoma that is resistant to standard therapy or for which no standard therapy is available
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
* Measurable disease or non-measurable disease and refractory to or intolerant of existing therapies (Part 1)
* Measurable disease as defined by RECIST 1.1 is required (Part 2)
Exclusion Criteria
* Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
* Major surgery or radiation within 3 weeks prior to study entry
* Last anti-cancer treatment within 4 weeks prior to study entry
* Active or history of clinically significant autoimmune disease that required systemic immunosuppressive medication
* Active or history of clinically significant gastrointestinal disease
* Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry
* Pregnant or breastfeeding female patients
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California, United States
City of Hope IDS Pharmacy
Duarte, California, United States
UCLA Department of Medicine: Hematology-Oncology
Los Angeles, California, United States
UCLA Hematology Oncology - Santa Monica
Santa Monica, California, United States
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)
Aurora, Colorado, United States
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
Aurora, Colorado, United States
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
Aurora, Colorado, United States
START Midwest
Grand Rapids, Michigan, United States
Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavillion
New York, New York, United States
Evelyn H. Lauder Breast and Imaging Center
New York, New York, United States
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Christus Santa Rosa Hospital
San Antonio, Texas, United States
NEXT Oncology
San Antonio, Texas, United States
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GUCY2C
Identifier Type: OTHER
Identifier Source: secondary_id
C3861001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.